Target intelligence / Profile preview

Pathogenic bacterium in gut

Molecular classification
Other (not a single molecular entity; refers to a group of diverse bacterial species)
01

Overview

The term "Pathogenic bacterium in gut" does not refer to a single molecule, receptor, or well-defined therapeutic target. Instead, it is an umbrella term encompassing any bacterial species within the gastrointestinal tract that has been associated with disease states or clinical infections. The human gut harbors hundreds of bacterial species—some are beneficial ("probiotic"), many are harmless ("commensal"), while others are considered potentially harmful ("pathogenic") due to their association with infections or outbreaks[1][2][3]. Common examples of **potentially pathogenic gut bacteria** include *Klebsiella pneumoniae*, *Bacteroides fragilis*, certain strains of *Escherichia coli* (such as EPEC and EHEC), among others[1][4]. These organisms can cause gastrointestinal diseases ranging from mild diarrhea to severe inflammatory conditions. However, whether a given bacterium acts as a pathogen depends heavily on host factors such as immune status and microbiome balance. Because this entry refers broadly to many possible organisms rather than one defined molecular target—such as an enzyme, receptor protein, transporter—it is not considered a canonical therapeutic target. Instead, interventions typically aim at modulating overall microbial populations using antibiotics (with risk for collateral damage), probiotics/prebiotics for competitive exclusion/immune modulation, or fecal microbiota transplantation. In summary: "Pathogenic bacterium in gut" is not itself a precise molecular entity but rather describes any member(s) of diverse taxonomic groups capable of causing disease when present in sufficient numbers or under conducive conditions[1][3][4].

Other names
Gut pathogenic bacteriaIntestinal pathogenic bacteriaPotentially pathogenic gut bacteriaHarmful intestinal bacteria
02

Biological functions

InfectionImmune modulation (context-dependent)Disruption of normal gut functionInflammation induction (in some cases)
03

Disease associations

InfectionInflammationGastrointestinal disease (e.g., diarrhea, colitis)Other (depends on specific pathogen)
04

Safety considerations

Therapeutic targeting of "pathogenic bacteria" risks disrupting beneficial commensal microbiota and can lead to antibiotic resistance or dysbiosis[4].

Beyond the preview

Go deeper on Pathogenic bacterium in gut.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic bacterium in gut.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call